Fluicell (FLUI) Q4 2025 earnings summary

Executive summary

• Achieved record quarterly net sales of 3,835 KSEK in Q4 2025, a 645% increase year-over-year, and first-ever positive post-investment cash flow of 1,271 KSEK in the quarter.

• Full-year net sales rose 223% to 6,002 KSEK, with total operating income up 47% to 15,510 KSEK compared to 2024.

• Strategic focus on regenerative medicine and technology platforms, with major partnerships and patent grants in 2025.

Financial highlights

• Q4 EBITDA improved to -7 KSEK from -1,735 KSEK; operating result improved to -94 KSEK from -1,830 KSEK.

• Q4 pre-tax profit reached 101 KSEK, up from -1,426 KSEK year-over-year.

• Full-year EBITDA improved to -8,025 KSEK from -15,403 KSEK; operating result to -8,395 KSEK from -15,842 KSEK.

• Cash flow from operations for the year improved to -4,944 KSEK from -15,669 KSEK.

• Year-end cash position was 2,262 KSEK, with an available credit line of 500 KSEK.

Outlook and guidance

• 2026 forecast expects result and cash flow in the range of -1 MSEK to 1 MSEK for the full year.

• Focus on expanding regenerative medicine partnerships, especially with Mayo Clinic and Breakthrough T1D.

• Continued growth targeted in technology sales, licensing, and research collaborations.